

Variant Surveillance– Cumulative Summary

Lineage (<i>WHO Classification</i>)	Proportion of Variant Sequenced from Dec 20, 2020 (%)	Proportion of Variant Sequenced in last 4 weeks (%)
Variant of Concern		
XBB.1.5 (Omicron)	4.0%	81.1%
XBB.1.9.1 (Omicron)	0.0%	5.3%
XBB (Omicron)	0.6%	3.6%
XBB.1.16 (Omicron)	0.0%	3.1%
XBB.1.5.1 (Omicron)	0.0%	2.4%
XBB.1.9.2 (Omicron)	0.0%	1.4%
BQ.1.1 (Omicron)	1.5%	0.7%
BQ.1 (Omicron)	1.9%	0.7%
CH.1.1 (Omicron)	0.0%	0.5%
BA.2 (Omicron)	11.7%	0.2%
FD.2 (Omicron)	0.0%	0.2%
BA.5 (Omicron)[#]	13.4%	0.0%
BA.2.75 (Omicron)	0.2%	0.0%
BA.4.6 (Omicron)	1.4%	0.0%
BF.11 (Omicron)	0.1%	0.0%
BF.7 (Omicron)	0.4%	0.0%
BN.1 (Omicron)	0.1%	0.0%
BA.2.75.2 (Omicron)	0.0%	0.0%
BA.4 (Omicron)	1.4%	0.0%
BA.1.1 (Omicron)	3.4%	0.0%
BA.2.12.1 (Omicron)	10.3%	0.0%
BA.1.1.529 (Omicron)	5.7%	0.0%
Variants Being Monitored (VBM)*		
B.1.617.2 (Delta)[§]	24.8%	0.0%
B.1.1.7 (Alpha)	7.2%	0.0%
P.1 (Gamma)	0.5%	0.0%
B.1.427, B.1.429 (Epsilon)	0.2%	0.0%
B.1.525 (Eta)	0.1%	0.0%
B.1.526 (Iota)	4.4%	0.0%
B.1.526.1	0.6%	0.0%
B.1.621, B.1.621.1 (Mu)	0.2%	0.0%
Other Lineages	5.9%	0.7%
Total Number of Specimens Sequenced**	78659	417

Omicron BA.5 includes all sublineages and aliases (BE.x and BF.x) except BF.7, BF.11 and BA.5.2.6; Omicron BA.4 includes all sublineages except BA.4.6; Omicron BA.2 includes all sublineages except BA.2.12.1, BA.2.75, BA.2.75.2, BN.1, XBB, XBB.1.5, XBB.1.5.1, XBB.1.9.1, XBB.1.9.2, XBB.1.16 and CH.1.1; Omicron B.1.1.529 includes BA.1, BA.3 and all sublineages (except BA.1.1 and its sublineages).


§ Delta includes B.1.617.2 and all AY variants.

* Variant of Interest or Concern were downgraded to this list with significant reduction in its proportions and evidence the variant does not pose a significant public health risk.


**Includes sequencing results reported by Commercial Labs (LabCorp, Aegis Sciences Corporation, Helix, Infinity Biologix and Quest Diagnostics) and the State Public Health Lab that have been submitted for surveillance purposes.

For CDC definitions of variant of concern and variant of interest visit: <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Concern>

COVID-19 Variant Surveillance by Week of Specimen Collection - Previous 8 Week Summary



COVID-19 Variant Surveillance by State Region- Previous 4 weeks Summary*



*Each regional chart represents the proportion of the specified variant lineage and is based on sequencing results from the 4 weeks prior to the week of April 15, 2023. There is an approximately 14-24-day time lag between specimen collection and report of sequencing results to NJDOH. "Other" represents additional lineages which include other COVID-19 variants not classified as variants of concern or variants of interest.

Includes all sequencing results reported by Commercial Labs (including LabCorp, Aegis Sciences Corporation, Helix, Infinity Biologix and Quest Diagnostics) and the State Public Health Lab that have been submitted for surveillance purposes.

Data reported is based on a subset of sampled specimens from NJ residents sequenced for COVID-19 variant surveillance.